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In this article we describe the rapid advances made in the 
molecular genetics of three inherited pigmentation disor­
ders: albinism, piebaldism, and vitiligo, all of which throw 
light on normal pigment cell function. The focus is on studies 
in mice, with comparison of data in humans. The critical role 
of tyrosinase (c-locus or human tyrosinase protein) in normal 
pigmentation and albinism has been reinforced by the clon­
ing and identification of mutations in tyrosinase and two 
other melanocyte-specific oxidoreductases structurally re­
lated to but functionally different from tyrosinase: the (b) 
brown-locus protein/gp75/catalase Band dopachrome tauto­
merase. Each possesses a distinct enzyme activity and yet the 
three share homology in strategic regions. Most of the point 
mutations that reduce or abrogate the respective enzyme ac­
tivities are located in those regions. Tyrosinase-negative al­
binism is caused only by defects in tyrosinase. A locus for 
human tyrosinase-positive albinism has been recently 
mapped to chromosome 15ql1.2 - q12, at a gene identified 
in mice as pink-eyed dilution. On the other hand, several genes 
encoding proteins critical for the proliferation of melano-
P igmentation in mammals is determined by melanin and depends on pigment synthesis by melanocytes as well as transfer and redistribution of melanosomes to keratino­cytes of epidermis and hair. Melanosomes contain mela­nocyte-specific enzymes and proteins whose function is 
gradually becoming clarified. The complexity of control of the 
pigmentary system is examplified by the gradations seen in the color 
of skin, hair, and eyes in humans and the multitude of coat color 
variations in animals. In mice, more than 50 genetic loci affecting 
pigmentation had been described by 1979 [1] and others have been 
identified since. These loci can be grouped into three major, not 
necessarily mutually exclusive, classes: 1) those controlling the 
amount and/or kind of melanin produced (eumelanin and pheome-
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cytes are known to control the piebald phenotype. So far 
identified are two membrane-receptor tyrosine kinases, c-Kit 
and PDGF-Rla, and the ligand for c-kit, MGF (mast-cell 
growth factor, also known as stem-cell factor, c-Kit-ligand, 
or steel factor). Mutations in W Ie-kit (white spotting), Phi 
Pdgfrla (patch), and SIIMGF (steel), lead to a reduction in 
receptor kinase activity and fai1ure of melanocytes to thrive 
and reach the skin during embryogenesis. Finally, mouse 
mutant models suggest at least two possible causes for viti­
ligo, a progressive loss of pigmentation that occurs after 
birth. In one mutant, the B'I (light) mouse, the cyclic death of 
hair melanocytes may be due to the toxicity of intermediates 
and byproducts of melanogenesis in the presence of a dys­
functional b-locus protein. In the other model, the "vitiligo 
mouse," in which the allele vit has been assigned to the 
microphthalmia (mi) locus, the loss of melanocytes may be 
caused by defective signal transduction, because in addition to , 
vitiligo mivillmivil mice have extensive piebaldism. ] Invest I 
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lanin); 2) those affecting the migration, proliferation, and survival 
of melanocytes; and 3) those reflected in the shape and ultrastruc­
ture of melanocytes. This review focuses on the first two classes that 
are re(,resented by albinism, piebaldism, and vitiligo. Recent re­
views l2,3] provide further information on this subject. This review 
updates an article published in Pigment Cell Research [4]. 
ALBINISM 
Albinism is a generalized absence or drastic reduction of pigment in 
otherwise normally distributed pigment cells, including those of 
the eye. Striking advances have been made in the area of genes 
affecting melanogenesis, more specifically, the genes for tyrosinase, 
the brown-locus protein, and dopachrome tautomerase (DT). Signifi­
cant homologies in the amino acid sequences suggest that these 
three melanosomal oxidoreductases have originated from a com­
mon ancestor gene, even though they are located on different chro­
mosomes. However, tyrosinase has emerged as the only enzyme 
absolutely necessary for melanin pigmentation and tyrosinase dys­
function as the only cause of tyrosinase-negative oculocutaneous 
albinism (OCA). The other two enzymes modify the kind and 
amount of melanin produced and, in the case of the b-Iocus protein, 
can also affect the viability of melanocytes. Our aim in discussing 
these three enzymes together is to show that the tyrosinase muta­
tions identified in OCA in both humans and mice are located in 
x;egions highly conserved among the three proteins, implying a 
common three-dimensional structure critical for the normal func­
tion of these enzymes. 
Cloning of cDNAs and Chromosomal Mapping of Tyro­
sinase, the b-Locus Protein and Dopachrome Tautomerase 
Four melanocyte-specific gene products, tyrosinase, b-Iocus protein, 
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dopachrome tautomerase, and Pmel 17, were cloned by screening 
normal or malignant melanocyte cDNA expression libraries with 
antibodies raised in rabbits against hamster tyrosinase by Dr. S. 
Pomerantz [5-9]. The reason for the multiple recognition by the 
polyclonal antibodies may be impurity of the original preparation 
used in the immunization. because these proteins are presumed to be 
present as a complex in the melanosomal limiting membrane [10]. 
An alternative explanation is that the immunogen was tyrosinase 
but the unglycosylated proteins produced by the bacterial expres­
sion libraries expose shared epitopes recognized by the antibodies. 
In support of the latter possibility is our inability to reveal any 
protein other than tyrosinase in immunoprecipitation and immun­
oblotting experiments with extracts from normal and a:lbino 
human, mouse, and chicken melanocytes [11-16]. 
The deduced amino acid sequences show that the three enzymes 
are glycoproteins of similar size, with a putative signal peptide, 
membrane-spanning domain, and presumptive catalytic regions, 
with conserved positions of histidine and cysteine, some of the sites 
for glycosylation, and an overall identity of 40% [5-9,17-221. 
Tyrosinase was confirmed to be encoded by a single gene in both 
mice and humans [5,18,20-22]. Mouse tyrosinase maps to the ,­
locus on chromosome 7 [5,20,22,23], and human tyrosinase (TYR) 
to chromosome 11, region q14 - q21 [23]. The mapping of the 
structural gene for mouse tyrosinase to the ,-locus on chromosome 7 
has once and for all overthrown the notion that this locus encodes a 
tyrosinase regulatory protein [24,25]. An additional site of human 
tyrosinase-related sequences was detected on the short arm of chro­
mosome 11, near the centromere (region p11.2 - cen) [23] that 
harbored a pseudogene. Characterization of the tyrosinase pseudo­
gene showed that it contained only exons IV and V because only 
these two were recognized and amplified by the polymerase chain 
reaction [26]. The clone originally isolated by Shibahara et al [17] as 
tyrosinase is identical to the independendy cloned TRPl (tyrosinase 
related protein 1) [6], was mapped to the brown locus on mouse 
chromosome 4 [6,271 and to human chromosome 9 [28]. The mur­
ine b-Iocus protein is identical to human gp75. a highly abundant 
melanocytic glycoprotein [12,29]. Dopachrome tautornerase, an­
other abundant melanocyte-specific protein, is represented by the 
clone TRP2 and has been mapped to mouse chromosome 14 at the 
slaty locus [7]. 
Despite the significant homology between tyrosinase and the 
b-Iocus protein, the two genes are different in structure and pro­
moter sequences. Whereas the tyrosinase gene contains five exons 
and is estimated to be longer than 70 kb [20], the gene at the brown 
locus contains seven [30] or eight [31] exons and is only 15 kb [30] 
or 18 kb [31] in length. The promoter regions are of similar sizes; 
that of tyrosinase is contained within 270 bp [32,33] and that of the 
brown-locus protein within 370 bp 5' of the translational start site 
[30,31]. Surprisingly, no classical cyclic adenosine monophosphate 
(cAMP) responsive element binding (CREB) protein consensus se­
quences have been found in the tyrosinase promoter despite the 
increase in tyrosinase and its messenger RNA (mRNA) and another 
melanocyte-specific mRNA, Pmel 17, in response to cyclic AMP 
[8,14,19]. The 11-bp motif, 5'-AGTCATGTGCT-3', found at po­
sitions -44 to -34, and -107 to -96, in the promoters for the 
b-Iocus and ,-locus genes, respectively, was shown to be a necessary 
positive regulatory element in melanocyte-specific expression and 
was termed the M-box [34]. This name may not be entirely appropri­
ate, because a construct containing two copies of the "M-box" up­
stream from the thymidine kinase promoter linked to /J-Gal permit­
ted expression of the transfected reporter gene even more strongly 
in non-melanocytes UEG3 cells) than in B-16 melanoma cells [34 J. 
Moreover, although electrophoretic band shift analyses detected a 
nuclear factor from B-16 melanoma cells that bound specifically to 
this motif, similar binding activity was found in nuclear extracts 
from NIH 3T3 fibroblasts [34]. The existence of an apparendy 
M-box -specific nuclear activating factor in non-melanocytes in the 
face of the so far unique occurrence of the M-box sequence in two 
otherwise quite distinctive promoters for two melanocyte-specific 
genes remains a puzzling enigma. 
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Functions of Tyrosinase, the Broum-Locus ProteiD. and Do­
pachrome Tautomerase Tyrosinase is essential to melanogene­
sis. The enzyme catalyzes three reactions in vitro: hydroxylation of 
L-tyrosine to L-dihydroxy-phenylalanine (L-dopa) l35], and oxida­
tions of L-dopa to L-dtja quinone [35] and 5,6-dihydroxyindole to 
indole-5,6 quinone [36 . Tyrosinase is sufficient for melanin synthe­
sis in vitro and may s ce also in vivo, as shown by transfection of 
tyrosinase complementary DNA (cDNA) into fibroblasts, and 
mammary carcinoma cells, as well as into amelanotic melanoma 
cells and albino melanocytes, turning the non-melanocytic or ame­
lanotic pigment cells into highly pigmented ones [21,37 -41]. Also, 
tyrosinase minigenes injected into fertilized eggs from an albino 
mouse strain yielded normally pigmented transgenic mice [42,43], 
and a retroviral vector carrying the human tyrosinase gene into 
Balb/c albino embryos gave rise to patches of pigmentation in adult 
mice [44], indicating that the albino melanoblasts incorporated 
these genes and became pigmented in a normal fashion. The organ­
elles into which the melanin has been deposited have not been 
identified. In the case of albinos, these are assumed to be the albino 
(pre)melanosomes. In the cells of non-melanocytic origin the mela­
nin may be in lysosomes, which have an acidic internal pH 
that would favor initiation of melanogenesis [45], or in peroxi­
somes. Both human and murine tyrosinases have the presumptive 
peroxisomal targeting sequence, SHL [46], at the carboxy termi­
nus [47]. 
In melanocytes, melanin production is modulated by mutations 
both inside and outside the tyrosinase locus, indicating the presence 
of enzymes or agents that positively or negatively regulate tyrosin­
ase activity and/or enhance or obstruct the synthesis of melanin. 
Such an enzyme was suggested to be the b-Iocus protein/gp75 
shown to be able to degrade H202 and thus given the tentative name 
catalase B [12]. H202 is probably formed during the catalytic con­
version of tyrosine to melanin precursors and melanin [48] and, 
unless removed, can destroy the precursors and melanin. The 
brown-locus protein/gp75 is not another tyrosinase [49,50] because 
it does not have tyrosinase activity in vitro [12,51-53] and tyrosinase 
activity remains absent from amelanotic human melanoma or breast 
carcinoma cells transfected with the cDNA encoding the wild-type 
b-Iocus protein [37]. Moreover, human and murine albino melano­
cytes carrying mutations in the ,-locus but possessing an active 
wild-type b-Iocus protein/gp75/catalase B have no tyrosinase activ­
ity, whereas melanocytes carrying the wild-type allele for the ,­
locus and mutant b-allele with a null mutation exhibit normal levels 
of tyrosinase activity [11,13,16]. 
The brown-Iocus/gp75/catalase B appears to be a highly anti­
genic glycoprotein. Monoclonal antibodies against it have been 
raised inadvertendy in four independent laboratories by the immuni­
zation of rodents with crude mixtures of melanosomal proteins in 
hopes of raising antibodies against tyrosinase ([51,54,55] and per­
sonal communication by Dr. K. Jimbow, Edmonton, Alberta, Can­
ada). This antigenicity may be due to a heme- or porphyrin-bound 
epitope [12] known from other systems to evoke an intense immune 
response [56]. Heme-containing oxidoreductases have been identi­
fied as autoantigens in autoimmune thyroiditis [57] and idiopathic 
autoimmune hepatitis [58], and catalase B/gp75 is a melanoma-as­
sociated autoantigen [29]. 
Dopachrome tautomerase [59] was discovered more than a decade 
ago as a "dopachrome conversion factor" [60,61], was cloned as 
TRP 2, and mapped to the slaty locus on mouse chromosome 14 [7]. 
The enzyme catalyzes the tautomerization of dorachrome to 5,6-
dihydroxyindole-2-carboxylic acid (DHICA) [61 rather than con­
version to 5,6-dihydroxyindole. DHICA is thought to be incorpo­
rated into melanin direcdy or as its indole quinone derivative [62]. 
The murine slaty point mutation predicts a single substitution of 
Argt!H to GIn in a presumptive metal-binding domain [7]. Argt!H is 
conserved between murine wild-type DT and tyrosinase [7]. As the 
name implies, the phenotype of slaty is slate gray, lighter than the 
black wild type, and is assumed to be due to the approximately 
threefold or greater reduction in DT activity causing the incorpora­
tion of 5,6-dihydroxyindole in favor of DHICA [62]. 
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Figure 1_ Murine Balbi e albino (ele). This e-locus mutation causes complete failure of pigment formation (the red eyes appear dark in this black-and­
white photograph) [1]. Tyrosinase has no detectable activity because of a missense mutation (G387 � C) substituting Cys85 with Ser [19,63 -65] in a region 
highly conserved between tyrosinase, DT, and b-locus proteinl gp75 I catalase B (b-locus). Immunoprecipitated tyrosinase from cultured albino melano­
cytes (left) is low in abundance and appears mostly as degradation products [II]. Cys86 in catalase B is the site of the b-mutation causing substitution with 
Tyr [27,67]. 
Tyrosinase Mutations 
Tyrosinase in Albino Miee: Recent molecular and biochemical analy­
sis of melanocytes carrying mutations at the tyrosinase gene have 
greatly advanced our understanding of the basis for the albino phe­
notype. In inbred albino (ele) mice, tyrosinase activity is not detecta­
ble, and the immunoprecipitated protein appears mostly as two 
low-molecular-weight degradation products at extremely low 
levels, suggesting severe sensitivity to proteolytic digestion [11] 
(Fig 1). Sequence analysis of the cDNA indicates a point mutation at 
exon 1: transition of G387 to C, substituting Cys85 with Ser [19,63-
65]. These cysteine and flanking amino acids are identical with 
those of the brown-locus protein and DT, with the exception of one 
conservative substitution (Fig 1; in all the figures, the numbering 
system does not include the putative signal peptide of 18 aa, and His 
of tyrosinase is taken as the first residue at the amino terminus as 
predicted from sequence analysis and as shown by direct sequencing 
of the protein [66]). This segment is part of the sequence Cys­
GlyXCys, which may be a heme- or porphyrin-binding domain 
[12]. In the murine brown-locus b mutation, Cys86 is replaced by Tyr 
[27,67] (Fig 1). The Balble albino mouse is homozygous for this 
mutation in addition to being homozygous for the albino mutation. 
Pigment cells from mice homozygous for the b mutation have little 
or no catalase B activity [12]. In homozygous bib animals that have 
wild-type tyrosinase, the coat is brown instead of black, probably 
because of a lower ratio of eumelanin to pheomelanin. These exam­
ples show that point mutations in the highly conserved domains in 
the genes for tyrosinase, catalase B, and dopachrome tautomerase 
cause severe reduction in enzyme activity. 
Another tyrosinase mutation analyzed at the nucleotide and pro­
tein levels is in the Himalayan mouse (d'lch) (Fig 2). In himalayan 
melanocytes, tyrosinase activity is easily abolished by slight in­
creases in temperature at physiologic ranges or on cell lysis in vitro, 
regardless of the method used to break down the melanocytes [11] 
(Fig 2). Analysis by immunoprecipitation and sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis showed that the post­
transcriptional modification of the protein, i.e., the addition of car­
bohydrate residues, was deficient [11] (Fig 2). Sequence comparison 
of wild-type and mutant tyrosinase cDNAs revealed a point muta­
tion at exon 4: transition of A 1342 to G, which would substitute Arg 
for His402 [68]. Again, the segment of His402 and eight flanking 
amino acids is identical in tyrosinase, the brown-locus protein, and 
DT (Fig 2), suggesting a domain important for maintaining the 
three-dimensional structure of the proteins andlor the binding of 
copper (a metal critical for tyrosinase activity) or the iron in heme (a 
prosthetic group in many mammalian hydroperoxidases and oxido­
reductases). It is thus possible that the loss of His402 in himalayan 
tyrosinase leads to structural abnormalities that reduce the effi­
ciency of glycosylation. The reduction in carbohydrate residues, in 
tum, would confer instability on the protein, hence reduction or 
loss of activity. 
Tyrosinase in Human Oeuloeutaneous Albinism: The sequencing of 
human albino tyrosinase has shown the existence of diverse but not 
r�dom mutations in the tyrosinase gene. Several human albino 
.missense mutations in tyrosinase have been identified in regions 
conserved between DT [7], b-locus protein/gp75/catalase B, and 
tyrosinase ([69-72]; reviewed in [72,73]) (Fig 3). Several frame 
shift mutations due to nucleotide insertions or deletions introducing 
early tertnination signals have been reported ([13,74,75]; reviewed 
in [72,73]). The predicted truncated protein was verified in one of 
these cases as an immature, smaller than normal, molecular species 
[13]. Likewise, the lack of recognition by antibodies directed against 
a 14-amino acid peptide comprising the carboxy terminal domain of 
human tyrosinase (anti-PEP7) [49] is in agreement with the predic­
tion that the protein suffered truncation in this domain [13]. The 
melanocytes had extremely low tyrosinase activity. 
Dysfunction of a gene other than tyrosinase in albinism was in­
ferred from the observation that offspring of tyrosinase-negative 
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Pigure 2. Murine himalayan (tit). This c-Iocus mutation causes a white coat color except at extreme, cool body parts (photograph ) [1). Himalayan 
tyrosinase is temperature sensitive, even in the physiologic range (graph ) [11) because of a missense mutation (A 13'2 -+ G) substituting His401 with Arg (68) 
in a region conserved between tyrosinase, DT, and catalase B (b-Iocus). Gel on the left-hand side shows tyrosinase proteins (arrows) from cultured wild 
type (CIC) and himalayan melanocytes (I, light; d, dark himalayan melanocytes). Radioactive cell extracts were subjected to immunoprecipitation with 
anti-tyrosinase antibodies, electrophoresis, and fluorography. The himalayan tyrosinase appears mostly as the unprocessed species (lower tyrosinase band) .  
The protein is deficient in carbohydrate residues (right-hand gel) [11). 
and tyrosinase-positive albinos were pigmented. The recently 
cloned murine gene pink-eyed dilution (p), identified as the murine 
homologue of a gene mapping to human chromosomal region 
15q 11.2-+q 12 may well be such a gene [76]. This region is linked to 
a tyrosinase-positive oculocutaneous albinism locus [135], and a 
partial deletion in this gene was recently identified in an individual 
with tyrosinase-positive albinism [136].The predicted protein pos­
sesses 12 hydrophobic domains capable of spanning a lipid bylayer, 
suggesting that it is associated tightly with the melanosomal mem­
brane. The pink-eyed dilution transcripts were abundant, as expected, 
in cultured melanocytes, and neonatal and adult eye tissue, but were 
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Pigure 3. Tyrosinase mutations in human OCA [69-73) in regions of 
high homology between human and mouse tyrosinase, DT, and b-locus 
protein/gp75/catalase B (b-locus). The sequences given represent the 
mouse proteins as aligned by Jackson et al [7]. Asterisk, site of the mouse 
himalayan mutation (His�2 -+ Arg). The region in brackets indicates a 
putative copper binding site. 
present also in fetal, neonatal, and adult brain, adult testis, and 
ovary. Homology to bacterial proteins suggests that the p-encoded 
protein acts as a transporter for tyrosine and/or DOPA, the sub­
strates for tyrosinase [136]. 
Another mouse gene, pallid, whose dysfunction causes hypopig­
mentation due to immature and sparse melanosomes, was recently 
identified as the locus for erythrocyte membrane protein 4.2 [137]. 
The pallid phenotype produces defects in two other subcellular or­
ganelles, platelet dense granules and kidney lysosomes. The 4.2 
pallidin protein belongs to the family of trans glutaminase enzymes, 
but lacks trans glutaminase activity [137]. This homology and the 
findings that it is N-myristylated and localized in melanosomes, 
suggests that defects in pallidin can be the cause of human diseases 
associated with a spectrum of storage pool deficiency such as the 
Hermansky-Pudlak syndrome and Chediak-Higashi disease [137]. 
PIEBALDISM AND VITILIGO 
Piebaldism, epitomized by the white forelock in hurnans and white 
spotting in animals, is characterized by a reduction in the number of 
pigment cells in well-delineated patches of skin, down to complete 
absence. The congenital white spotting is stable and the pattern 
determined during embryogenesis. Vitiligo is patchy post-natal loss 
of pigment cells, acquired in childhood and adolescence, or even 
later in life, and in rare cases may progress to total depigmentation. 
Several mouse models exist for the study of piebaldism and vitiligo 
[1,77]. Mutations that result in piebaldism have been identified at 
minimally nine independent loci [1]. These are known as steel (SI, 
chromosome 10), piebald spotting (5, chromosome 14), lethal spot­
ting (Is, chromosome 2), belted (bt, chromosome 15), microphthal­
mia (mi, chromosome 6), and several that are clustered on chromo­
some 5, including dominant white spotting (W), patch (Ph), 
rump-white (Rw), and recessive spotting (rs). So far, only the W, 
Sl, and ph mutations have been studied at the molecular level. 
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Figure 4_ Murine and human piebaldism. Left: Western blot with anti-phosphotyrosine antibodies of cell extracts from human melanocytes deprived (0) 
or stimulated for 5 min (5') with MGF. The blot shows tyrosyl-phosphorylation of p1451ri" MAP-kinase (p40 .... pk), and several other proteins in response 
to MGF [95]. Middle: photograph of UI" lUI" mouse [1). R.ight: schematic representation of ,-kit and localization of mutations in murine (W) and human 
(kit) piebaldism. Hatched areas in intracellular regions of the receptor indicate kinase domains. SP, signal peptide; TM, transmembrane domain; A TP bdg.s, 
ATP binding site; KI, kinase-insert. Mutations as reported [79,80,96-99,101,114-116]. Diagram adapted from [97]. 
Among the possible animal models for vitiligo, molecular data are 
available for the murine n" mutation. None exist for human vi­
tiligo. 
White Spotting, c-leit, and MGF Mutations at the dominant 
white spotting (W) and steel (Sl) loci affect the proliferation of me­
lanoblasts as well as hemopoietic stem and primordial germ cells 
during embryogenesis [78]. Homozygous mice are characterized by 
extensive white spotting and suffer from anemia and sterility. The 
identification of c-kit and the kit-ligand, mast cell growth factor 
(MGF), as the genes at the W and Sl loci was an important step 
toward elucidating the mechanism by which W and SI mutations 
exert their pleiotropic effects [79 -88]. MGF is also referred to as the 
kit-ligand, stem-cell growth factor, or steel factor because it is en­
coded at the steel locus [81-88]. 
C-kit encodes a transmembrane receptor tyrosine-kinase with ho­
mology to CSF-l-R and PDG F-R (receptors for colony-stimulating 
factor 1 and platelet-derived growth factor) [89,90]. Ligand binding 
causes dimerization of the receptor and activation of the kinase 
through autophosphorylation, followed by a cascade of tyrosine 
phosphorylations on several intermediates [89,91-95] (Fig 4). Ty­
rosine-phosphorylated intermediates in the c-Kit signal-transduc­
tion pathway were identified as phosphatidylinositol (PI) 3' -kinase, 
Rafl, and phospholipase C)' (PLC),), all of which become associated 
with the receptor on ligand binding [91,92,94], and the serine/ 
threonine kinase MAP kinase/ERK (microtubule-associated pro­
tein 2-kinase/extracellular signal-regulated kinases [94,95]). 
The common phenotypic denominator of mutations at the W 
locus is reduced c-Kit receptor tyrosine kinase activity [79,80,96-
98]. The reduction may be due to a decreased abundance of receptor 
protein with apparently normal kinase activity (the dominant alleles 
W44, W .. , and WS1), or expression at normal levels of a defective 
enzyme (the dominant homozygous-lethal alleles WJ7 and W42, the 
moderately dominant homozygous alleles W41 and WSS, and the 
heterozygous W /wv). The dominant-negative characteristic of the 
W mutations was confirmed by recapitulating the W42 heterozy­
gous phenotype in c-ki�2 transgenic mice [99]. In one case (W44, 
Fig 4), reduced abundance was due to a rearrangement within the 
c-kit gene as a result of an insertion, affecting the levels of ,-kit 
transcripts [79]; in another case, Wl9, c-kit, and the adjacent gene 
Pdgf-ra are deleted [79,80,100]. Reduced activity is due to missense 
mutations causing substitutions at highly conserved positions in the 
kinase domain [97,98,101] (Fig 4). In the case of the W42, WJ7, and 
W41 mutations, the ligand-induced association with substrate pro­
teins PI 3' -kinase and PLC), is abolished or reduced, respectively 
[92,102]. In view of the finding that PI 3'-kinase binds to the ki­
nase-insert domain of c-Kit ([103], see Fig 4), it is likely that ligand­
induced c-Kit autophosphorylation alters the conformation of the 
receJ?tor in such a way as to facilitate the association with substrates 
[103J. Recent studies in which anti-c-Kit blocking antibodies were 
injected into pregnant mice showed that c-Kit kinase was important 
during a brief, single-day post-coitum period, around day 14.5 when 
melanocytes proliferate in the mesoderm before entering the epider­
mis [104]. Injection of the antibodies at an earlier stage of develop­
ment when melanocytes exit from the neural crest, or later on dur­
ing embryonic life, had no effect on pigmentation. In addition, in 
situ hybridization with probes for ,-kit and b-locus protein has 
shown that kit is expressed in melanocytes of day 10 embryos, at 
which stage the pigment cells are already in the presumptive dermis, 
supporting the conclusion that the receptor kinase is not critical for 
early migration but rather for the proliferation and survival of mela­
nocytes in the skin [105 -108]. Interestingly, the white-spotted phe­
notype caused by the W" mutation is corrected in part in the inbred 
offspring of ret-transgenic W" /W" mice [109]. The ret oncogene is a 
constitutively active receptor-tyrosine kinase with homology to c­
kit that apparently stimulates the same signal-transduction pathway 
induced by c-Kit in melanocytes. 
The prediction that mutations in c-kit might also be the cause for 
human piebaldism was based on chromosome studies of piebald 
patients with additional gross developmental abnormalities, which 
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showed deletion or translocation involving chromosome 4q21 
[110,111], the region to which c-kit has been assigned [89,90]. 
DNA analyses from two piebald patients (one with other abnormali­
ties and the other otherwise normal) revealed a deletion encompass­
ing the entire coding region of c-kit and involving also the closely 
linked gene PDGF-R/OI., reminiscent of the murine Wf' mutation 
[112,113]. Furthermore, identification of missense mutations, dele­
tions, and duplications have demonstrated that, indeed, dysfunction 
of kit is the cause of some human piebaldism. Missense mutations 
include Glu582 --+ Lys (as in the murine W'7 mutation) [114], 
Gly664 --+ Arg, and Phe584 --+ Leu [115,116], possibly disrupting 
the tyrosine kinase domain, and Gly601 --+ Arg in the putative aden­
osine triphosphate binding site (Bernstein et ai, in preparation) (Fig 
4). Two other piebald individuals suffered frame shifts that led to 
the formation of early termination signals with the predicted conse­
quence of eliminating the kinase-inserts and kinase domains at the 
respective carboxyl termini [116]. These observations, and the dem­
onstration that KIT kinase is important for the proliferation of 
normal human pigment cells and, possibly, maintenance of the dif­
ferentiated melanocytic phenotype in vitro [95], support the conclu­
sion that human melanocytes are dependent on c-KIT kinase for 
normal development. 
Mutations at the Sl locus, which encodes the Kit-ligand, MGF, 
cause similar changes in phenotype in the same three cell lineages as 
do mutations in the W locus. MGF, produced by stromal cells, exists 
as cell-surface and soluble forms, both with equal mitogenic po­
tency [73 - 75]. Melanocytes and mast cells derived from wild-type 
or Sl mutants fail to grow on steel fibroblasts or steel-derived extra­
cellular matrix, but thrive on wild-type fibroblasts or wild-type 
matrix [117,118]. The absence of surface-bound MGF from steel 
fibroblasts was confirmed by the cells' inability to bind soluble c-kit 
[88]. The S[4 mutation is a 4.0-kb deletion of the transmembrane 
and intracellular domains in the MGF gene [119,120]. This finding 
provides evidence that, in vivo, cell surface MGF, rather than the 
soluble form, has a critical role in normal development. 
The Patth/Pdgfra Locus The patch locus in mice encodes the 
alpha subunit of the receptor for platelet-derived growth factor 
(PDGF-R/OI.), another receptor tyrosine kinase; the piebald Ph mu­
tation is a deletion [100,121]. Because of the high sequence homol­
ogy, structural and functional similarities, and the close topographi­
cal proximity of patch and c-kit on chromosome 5, it is possible that 
the two receptor kinases have evolved from tandem duplication of a 
single ancestor gene. The Wf'H mutation is a deletion of both c-kit 
andPDGF-R/Oi. [79,80,100,121]. The white spotting in Wf'H mice 
is less pronounced than in the W or Ph mutants, suggesting that an 
imbalance in the expression of the respective receptors is more dele­
terious to melanocyte development than a reduced but balanced 
activity [100]. 
It is thus possible that receptor tyrosine kinases act in concert and 
that a deficiency in one reduces the efficiency of others. In support 
of this idea is the recurrent finding that normal human and murine 
melanocytes will not be sustained in culture by only one melanocyte 
peptide growth factor unless the medium is supplemented with 
cAMP, 12-0-tetradecanoyl phorbol-13-acetate, or an additional 
melanocyte peptide growth factor (reviewed in [122]). It appears 
that the second growth factor cannot be chosen at random from the 
list of melanocyte-stimulating peptides but that there are distinct 
complementary pairs, such as bFGF plus hepatocyte growth factor 
(HGF) [123]. 
Whether inactivation of the PDGFRA can be as deleterious to 
human pigmentation as it is in mice is not yet clear. Neonatal 
human melanocytes do not express PDGFR/OI. mRNA in culture 
[124] and do not proliferate in response to PDGF whereas murine 
melanocytes do (our unpublished results). Whether the PDGFRA is 
expressed in human melanoblasts during embryogenesis or prior to 
hair follicular renewal, is a subject that has not been investigated. 
Together, the genetic and biologic data suggest that melanocytes 
depend on more than one receptor kinase during the course of 
embryonic devel0l'ment. The cloning of additional receptor tyro­
sine kinases may furnish clues to the nature of the gene products in 
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other loci affecting pigmentation. For example, two new receptor 
tyrosine kinases, designated kinase insert domain-containing recep­
tor (KDR) and fms-like tyrosine kinase 3/fetal liver kinase 1 (Flt3/ 
Flk1) with a structure typical for receptors from the c-kit family, 
were cloned recently [125-127]. The KDR gene maps to human 
chromosome 4 and mouse chromosome 5 [125] and Flt3/Flk1 to 
mouse chromosome 5 next to c-kit and PDGF-R/OI. [1271. KDR 
and/or Flt3/Flk1 could well be the human equivalent of rump­
white or recessive spotting, the two white spotting loci linked to 
c-kit on mouse chromosome 5, but Northern blot analysis of human 
melanocytes and three melanoma cell lines failed to detect the KDR 
and Flt3/Flk1 messages (B. Terman and D. Birnbaum, respectively, 
in collaboration with R. Halaban, unpublished results), indicating 
that these two kinases may not play a role in human melanocytes. 
Premature Graying and B" Measured against this wealth of 
information, knowledge of molecular events in vitiligo is minus­
cule. The prevalent hypothesis for the cause of vitiligo is a combina­
tion of melanocytic autotoxicity and secondary immune response. 
The best advanced model for this view is the Smyth chicken [128], 
for which no molecular data are available at this writing. The viti­
ligo mutation in the C57/BL Ler-vit/vit mouse [77] was shown to 
be allelic with the microphthalmia mi locus [129] and may, there­
fore, be related to a signal-transduction pathway. The mi mutation 
was suggested to be in a gene encoding a receptor-tyrosine kinase 
signal-transducing protein activated by both, the ,-Kit and c-fms 
[130]. Mi-mutant mice are phenotypically piebald, like W and Sl 
mutants, and osteopetrotic like c-jms mutants; in addition, ectopic 
expression of c-jms can substitute for a defective Wallele but not a 
defective mi [130]. 
Another murine model for early graying is the B" (light) mutation 
at the b-Iocus [110,111] (Fig 5). The phenotype produced by the 
light mutation is associated with clumping, irregular distribution, 
and reduction in number of melanosomes, ending in the premature 
death of all follicular melanocytes [131,132]. The result is a lightly 
pigmented hair tip on an almost white hair shaft. The mutation is a 
substitution of Arg14 by Cys near the carboxy terminus of the puta­
tive signal peptide of b-Iocus protein/gp75/catalase B [133]. The 
Arg itself is not conserved between tyrosinase and the b-Iocus pro­
tein, but the flanking Leu and two Cys residues are (Fig 5). Interest­
ingly, this Arg is conserved between the b-Iocus and Pmel 17 pro­
teins [9], the latter having been mapped to the silver locus [9]. The 
silver mutation does not reduce the amount of melanin produced but 
is associated with an altered morphology of the melanocytes in vitro 
(our unpublished observation). At first, we thought that the B" 
mutation might cause an increased sensitivity to proteolytic degrada­
tion [12]. However, in subsequent immunoblotting and immuno­
precipitation studies with a panel of antibodies to b-Iocus protein/ 
gp75/catalase B no structural differences between wild-type and 
light proteins were revealed. In contrast, the abnormalities in the 
b-Iocus brown mutant protein are readily detected as loss of the 
TMH-l epitope (Fig 5). 
Catalases in general exist as tetramers, and undenatured catalase B 
occurs as a homodimer or as part of a larger aggregate [12]. There­
fore, the B" mutation may create a condition similar to that de­
scribed for the c-Kit receptor tyrosine kinase: in heterozygotes the 
mutant protein may complex with and inactivate the normal wild­
type enzyme, causing what is known as transdominant or semido­
minant inheritance. Addition of a cysteine in a region of catalase B 
that already possesses two of these residues may affect the folding of 
the enzyme onto itself and/or disturb the interaction with other 
melanosomal enzymes rich in conserved cysteines (suggested to be 
an EGF-like repeat [7]) such as tyrosinase and dopachrome tauto­
merase. The melano-cytotoxicity inherent in the light mutation 
may be due to toxic intermediates and byproducts of melanogenesis, 
because destruction of melanocytes is observed in black (C57/BL) 
but not albino mice carrying the B" allele [133]. In contrast to the 
brown mutant form, the BI' protein retains the highly antigenic 
hemelike epitope [12], which once released from moribund melano­
cytes may invoke an autoimmune response against melanizing pig­
ment cells, resulting in the cyclic vitiligo of Bit mice. 
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CONCLUSION 
·b 
We have shown in this review that mutations at diverse loci, or 
within the same locus at diverse sites, can produce almost indistin­
guishable phenotypes. As a consequence, identification of human 
camers of such mutations for the purpose of genetic counseling will 
be more complicated than in some other inherited diseases for 
which single genetic markers are diagnostic. 
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